Skin of Color Update 30% Off Registration, Use Code: JDD30
Skip to main content
AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

APP-solutely Essential: Putting Corticosteroid Stewardship Into Practice

| Featured Articles, Featured Podcast, Latest News, Podcast, Podcast Highlights | No Comments
Guest: Douglas DiRuggiero  Corticosteroids remain one of dermatology’s most reliable workhorses, but good stewardship isn’t about putting the horse out to pasture. It’s about knowing when to ride, when to…
Journal of Drugs in Dermatology JDD featuring Topical Carboxytherapy as an Adjunct to Skin Recovery Post-CO2 Laser Fractional Resurfacing

Topical Carboxytherapy as an Adjunct to Skin Recovery Post-CO2 Laser Fractional Resurfacing

| Aesthetics, Featured Articles, Lasers & Light Devices, Latest News | No Comments
Post-Procedure Optimization: Enhancing Laser Resurfacing Outcomes With Topical Carboxytherapy  Have you read this recent article from the JDD regarding post-laser skin recovery protocols? As aesthetic dermatology continues to advance, optimizing…
Journal of Drugs in Dermatology JDD About The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas. The images is of tinea versicolor among different skin tones

Tune In to Clinical Innovation: Celebrating National Podcast Day with the JDD Podcast

| Featured Articles, Featured Podcast, Latest News | No Comments
Join JDD Podcast: Ask the Investigators as we celebrate a decade of dermatology insight with our trusted host, Dr. Adam Friedman National Podcast Day provides the perfect opportunity to highlight…

Leave a Reply